Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies

Summary: A current challenge is the emergence of SARS-CoV-2 variants, such as BQ.1.1 and XBB.1.5, that can evade immune defenses, thereby limiting antibody drug effectiveness. Emergency-use antibody drugs, including the widely effective bebtelovimab, are losing their benefits. One potential approach...

詳細記述

書誌詳細

出版年:	iScience
主要な著者:	Tetsuya Inoue, Yuichiro Yamamoto, Kaoru Sato, Yuko Okemoto-Nakamura, Yoshimi Shimizu, Motohiko Ogawa, Taishi Onodera, Yoshimasa Takahashi, Takaji Wakita, Mika K. Kaneko, Masayoshi Fukasawa, Yukinari Kato, Kohji Noguchi
フォーマット:	論文
言語:	英語
出版事項:	Elsevier 2024-04-01
主題:	Natural sciences Biological sciences Biochemistry Immunology Microbiology
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2589004224005844